Dr Reddy’s Laboratories Launches Limited Competition Product in U.S.
- Drug launch boost for Dr Reddy's Laboratories
- Launches limited competition product in the U.S.
- Analysts estimate incremental annual revenue of $25 million
Dr. Reddy's Laboratories launched Omeprazole and sodium bicarbonate capsules in the U.S. market – a therapeutic equivalent of Salix Pharmaceuticals' Zegerid capsules. Zegerid is an antacid and clocked in sales worth $306.7 million in the U.S. for 12 months ended in May 2016, according to IMS Health.
The move was largely anticipated, given that the Zegerid patent expired on July 15, 2016. Dr Reddy's Laboratories had a settlement with the innovator (patent holder), Valeant Pharmaceuticals to launch its generic version on 16 July 2016.
It is a positive development for Dr Reddy's Laboratories given that it is a limited competition product. Praful Bohra, analyst from Religare estimates this product can add $25 million annually on a sustainable basis to Dr Reddy's revenues.(assuming 70 percent price erosion, 20 percent market share). Bohra assumes it is a 4-5 player market.
We believe this can be an interesting near-term opportunity for Dr. Reddy's given favourable market dynamics (limited competition, increased market size post price hikes by Valeant).Praful Bohra, Analyst, Religare Capital Markets in his report dated July 15
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
